THO 0730 A Phase II Trial of Celecoxib Plus Chemotherapy (Docetaxel or Pemetrexed) in Patients with Previously Treated 'Cox Dependent' Recurrent Non-Small Cell Lung Cancer.

Trial Profile

THO 0730 A Phase II Trial of Celecoxib Plus Chemotherapy (Docetaxel or Pemetrexed) in Patients with Previously Treated 'Cox Dependent' Recurrent Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Celecoxib (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms SPORE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Feb 2013 Planned End Date changed from 1 Jan 2016 to 1 Dec 2019 as reported by ClinicalTrials.gov.
    • 06 Feb 2013 New source identified and integrated (Vanderbilt University Institutional Review Board: 070723).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top